Bioventus Inc (BVS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Bioventus Inc stock (BVS) is currently trading at $9.15. Bioventus Inc PE ratio is 26.18. Bioventus Inc PS ratio (Price-to-Sales) is 1.02. Analyst consensus price target for BVS is $15.00. WallStSmart rates BVS as Underperform.
- BVS PE ratio analysis and historical PE chart
- BVS PS ratio (Price-to-Sales) history and trend
- BVS intrinsic value — DCF, Graham Number, EPV models
- BVS stock price prediction 2025 2026 2027 2028 2029 2030
- BVS fair value vs current price
- BVS insider transactions and insider buying
- Is BVS undervalued or overvalued?
- Bioventus Inc financial analysis — revenue, earnings, cash flow
- BVS Piotroski F-Score and Altman Z-Score
- BVS analyst price target and Smart Rating
Bioventus Inc
📊 No data available
Try selecting a different time range
BVS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Bioventus Inc (BVS)
BVS trades 261% above its Graham fair value of $2.24, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Bioventus Inc (BVS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, institutional own.. Concerns around revenue growth and profit margin. Mixed signals suggest waiting for clearer direction before acting.
Bioventus Inc (BVS) Key Strengths (3)
77.23% of shares held by major funds and institutions
Good growth relative to its price
Paying $1.02 for every $1 of annual revenue
Supporting Valuation Data
Bioventus Inc (BVS) Areas to Watch (6)
Revenue growing slowly at 2.80% annually
Very thin margins, barely profitable
Thin operating margins with cost pressures present
Premium pricing at 3.2x book value
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Supporting Valuation Data
Bioventus Inc (BVS) Detailed Analysis Report
Overall Assessment
This company scores 47/100 in our Smart Analysis, earning a D+ grade. Out of 9 metrics analyzed, 3 register as strengths (avg 8.7/10) while 6 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., PEG Ratio, Price/Sales. Valuation metrics including PEG Ratio (1.15), Price/Sales (1.02) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Revenue Growth, Profit Margin, Operating Margin. Some valuation metrics including Price/Book (3.17) suggest expensive pricing. Growth concerns include Revenue Growth at 2.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 13.20%, Operating Margin at 13.80%, Profit Margin at 4.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 13.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Revenue Growth and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BVS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BVS's Price-to-Sales ratio of 1.02x sits near its historical average of 1.03x (29th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 4% below its historical high of 1.07x set in Mar 2026, and 4% above its historical low of 0.99x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Bioventus Inc (BVS) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Bioventus Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 568M with 3% growth year-over-year. Profit margins are thin at 4.0%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 37M in free cash flow and 37M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Bioventus Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Bioventus Inc.
Bottom Line
Bioventus Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Bioventus Inc(BVS)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Bioventus Inc., a medical device company, focuses on developing and commercializing clinical treatments that involve and enhance the body's natural healing process in the United States and internationally. The company is headquartered in Durham, North Carolina.